Allogene Therapeutics, Inc.
Allogene Therapeutics is a clinical-stage immuno-oncology company developing genetically engineered allogeneic T cell therapies for cancer and autoimmune disease. Its core idea is to create “off-the-shelf” CAR T products derived from healthy donors, so treatment can be delivered faster and at larger scale than autologous cell therapies made from a patient’s own cells. The company’s pipeline is still in development, with management highlighting upcoming clinical readouts expected in 2026 as potential validation points for the platform. Allogene is focused on a small number of lead programs, including cema-cel in large B-cell lymphoma and ALLO-329 in autoimmune disease, while also maintaining collaborations that support its gene-editing and biomarker strategy.
Fiscal year 2025 · change from previous year
Development 2019–2025
Business
Share of revenueEngineered T cell therapies designed to target hematologic cancers such as large B-cell lymphoma and other blood cancers.
Allogeneic T cell candidates intended to eliminate pathogenic autoreactive cells in autoimmune disorders.
Licensing and technology partnerships that support next-generation cell engineering and development.
Customers
Allogene does not sell commercial products today; its current “customers” are primarily clinical trial participants, investigators, and partner organizations that support development and regional rights. In oncology, the company is targeting patients with large B-cell lymphoma and other hematologic malignancies through clinical studies designed to test whether off-the-shelf CAR T can work in community and academic settings. In autoimmune disease, the target population is patients with severe autoimmune conditions where CD19-directed cell therapy could reset pathogenic immune activity. The company also relies on collaborators such as Foresight Diagnostics and its China-region partner structure to enable biomarker development, trial enrollment, and future regional commercialization.
Patients with hematologic malignancies, especially large B-cell lymphoma, enrolled to test cema-cel and related allogeneic CAR T candidates.
Patients with autoimmune disorders targeted by ALLO-329 and other next-generation CD19 programs to reduce pathogenic autoreactive cells.
Hospitals, cancer centers, and research sites that administer the company’s studies and generate the clinical data needed for regulatory progress.
Partners such as Foresight Diagnostics that provide MRD testing to identify eligible patients and support trial design.
Entities in greater China, Taiwan, South Korea and Singapore that hold rights to develop and commercialize licensed products in those territories.
Strategy
Allogene’s strategy is to prove that allogeneic, off-the-shelf CAR T can be safer, more scalable, and more practical than autologous cell therapy. Management is concentrating resources on a few core clinical programs, especially ALPHA3 in large B-cell lymphoma and ALLO-329 in autoimmune disease, rather than spreading capital across a broad pipeline. The company is also using partnerships to de-risk key dependencies, including MRD testing with Foresight Diagnostics and gene-editing capabilities through third-party technology agreements. A major near-term objective is to generate clinical readouts that can validate the platform and support future regulatory and commercial planning.
The company needs readouts that demonstrate biologic activity, safety, and feasibility of standardized allogeneic CAR T therapy.
Large B-cell lymphoma is the most advanced and commercially visible oncology opportunity in the pipeline.
Autoimmune disease could broaden the addressable market and diversify the company beyond oncology.
The company relies on external technologies and collaborators for gene editing, diagnostics, and regional rights.
Geography
Allogene is headquartered in the United States and conducts most of its development and corporate activity there, including clinical planning, R&D, and regulatory work. The company’s commercial geography is still limited because it has not yet launched a marketed product, but its strategic footprint extends into Asia through a licensing structure covering greater China, Taiwan, South Korea and Singapore. Management also highlighted expansion of ALPHA3 clinical activity into Canada and Australia, and possible EU/UK development work with Foresight Diagnostics, which broadens the trial footprint beyond the U.S. Geography matters because the company’s future value depends on regulatory approvals, trial execution, and partner performance across multiple jurisdictions rather than on current product sales.
Risks
Allogene faces the classic risks of a clinical-stage biotech company: no approved products, ongoing losses, and a need for substantial additional financing to fund development. Its lead programs are based on novel allogeneic cell therapy technology, so clinical outcomes, safety signals, and regulatory expectations are difficult to predict and could materially delay or derail commercialization. The company is also dependent on third parties for key technologies, clinical trial execution, and diagnostic support, which increases execution risk and reduces control over timelines. In addition, competition is intense in both oncology and autoimmune cell therapy, and larger or better-funded rivals could reach the market first or develop more effective and convenient therapies.
- Clinical and regulatory failure of lead programsImpact: CriticalLikelihood: High
ALPHA3, RESOLUTION, TRAVERSE and ALLO-329 are still in development, and novel cell therapies can fail on efficacy or safety.
Exposure: Lead oncology and autoimmune assets
- Need for substantial additional financingImpact: HighLikelihood: High
The company has recurring losses and must fund expensive clinical development before any product revenue exists.
Exposure: Development programs and corporate operations
- Competition in CAR T and autoimmune cell therapyImpact: HighLikelihood: High
Rivals may develop safer, more effective, or faster-to-market therapies and capture physician adoption first.
Exposure: Oncology and autoimmune markets
- Dependence on third-party licensors and collaboratorsImpact: HighLikelihood: Medium
The company relies on Cellectis, Servier, Foresight Diagnostics and others for essential technology and trial support.
Exposure - Manufacturing consistency and donor variabilityImpact: HighLikelihood: Medium
Allogeneic products depend on healthy donor cells and reliable manufacturing processes to ensure consistent product quality.
Exposure: Cell sourcing and production
Accounting
Judgemental itemsThe company estimates unpaid CRO, clinical, and manufacturing costs each period, and later true-ups can move expenses and liabilities materially.
Impact: Affects R&D expense and accrued liabilities
Revenue has been generated from the Overland license agreement and depends on performance obligations and timing of milestones or services.
Impact: Affects reported revenue and comparability across periods
Equity awards are a meaningful part of compensation in a development-stage biotech and can materially affect operating expenses.
Impact: Affects R&D and G&A expense
Asset values may need to be written down if programs change, facilities are underused, or expected future benefits decline.
Impact: Can create non-cash charges in operating expense
Similar listed companies
Publicly listed companies with a comparable business focus.
Caribou Biosciences, Inc.
CRBU · Biological Products, (No Diagnostic Substances)
Fate Therapeutics, Inc
FATE · Biological Products, (No Diagnostic Substances)
Fate Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf cellular immunotherapies built from human induced pluripotent stem cells (iPSCs).
Cellectis S.A.
CLLS · Biological Products, (No Diagnostic Substances)
Lineage Cell Therapeutics, Inc.
LCTX · Biological Products, (No Diagnostic Substances)
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing allogeneic, or off-the-shelf, cell therapies for serious ophthalmic and neurological diseases.
Cullinan Therapeutics, Inc.
CGEM · Biological Products, (No Diagnostic Substances)
Adicet Bio, Inc.
ACET · Pharmaceutical Preparations
Last updated: 24/09/2026